Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.7% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded down 0.7% on Wednesday . The company traded as low as $7.35 and last traded at $7.41. 5,964,234 shares were traded during trading, a decline of 7% from the average session volume of 6,419,481 shares. The stock had previously closed at $7.46.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Finally, Leerink Partners lowered their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Trading Down 0.4 %

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.99 billion, a PE ratio of -4.58 and a beta of 0.85. The business’s fifty day moving average price is $6.71 and its 200 day moving average price is $7.29.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same period in the previous year, the business posted ($0.43) earnings per share. The firm’s quarterly revenue was up 147.6% on a year-over-year basis. As a group, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the transaction, the chief executive officer now owns 762,656 shares in the company, valued at $4,697,960.96. The trade was a 2.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $6.84, for a total transaction of $78,297.48. Following the sale, the director now directly owns 7,109,875 shares of the company’s stock, valued at approximately $48,631,545. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 119,235 shares of company stock worth $802,988. 15.75% of the stock is owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in RXRX. Charles Schwab Investment Management Inc. raised its stake in shares of Recursion Pharmaceuticals by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after purchasing an additional 288,926 shares in the last quarter. FMR LLC raised its stake in Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after buying an additional 170,810 shares in the last quarter. Perceptive Advisors LLC bought a new position in Recursion Pharmaceuticals during the 2nd quarter worth approximately $5,769,000. Pier 88 Investment Partners LLC grew its position in shares of Recursion Pharmaceuticals by 442.1% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock worth $882,000 after acquiring an additional 109,210 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after acquiring an additional 167,302 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.